Association of anticoagulant use with clinical outcomes from crizotinib in ALK <scp> ‐ </scp> and ROS1 ‐rearranged advanced non‐small cell lung cancers: A retrospective analysis of <scp>PROFILE</scp> 1001-Reference-Cited by-同舟云学术

Association of anticoagulant use with clinical outcomes from crizotinib in ALK ‐ and ROS1 ‐rearranged advanced non‐small cell lung cancers: A retrospective analysis of PROFILE 1001

Published:2022-05-05 Issue:23 Volume:11 Page:4422-4429
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Ng Terry L.¹^ORCID,Tsui David C. C.²,Wang Sherry³,Usari Tiziana⁴,Patil Tejas²,Wilner Keith⁵,Camidge David R.²

Affiliation:

1. Division of Medical Oncology, Department of Medicine University of Ottawa Ottawa Canada

2. Division of Medical Oncology, Department of Medicine University of Colorado School of Medicine Aurora Colorado USA

3. Pfizer Oncology San Francisco California USA

4. Pfizer Milan Italy

5. Pfizer Oncology La Jolla California USA

Funder

Pfizer

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4789

Reference32 articles.

1. ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events

2. ALK -Rearranged Non–Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism

3. Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer

4. Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC

5. Association of ALK rearrangement and risk of venous thromboembolism in patients with non-small cell lung cancer: A prospective cohort study

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals;Current Problems in Cancer;2024-12

2. Crizotinib inhibits the metabolism of tramadol by non-competitive suppressing the activities of CYP2D1 and CYP3A2;PeerJ;2024-05-30

3. Non-bacterial thrombotic endocarditis in ROS1-rearranged lung cancer: a report of two cases;Translational Lung Cancer Research;2024-01

4. Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment;Drug Resistance Updates;2023-01